EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The phosphoproteomic landscape of the neurological manifestations in tuberous sclerosis complex

Marie Girodengo, Simeon R Mihaylov, Katarzyna Klonowska, Laura Mantoan Ritter, Helen R Flynn, J Mark Skehel, Elias Bou Farhat, Eleonora Aronica, Matthew White, David J Kwiatkowski, Sila K Ultanir, Joseph M Bateman

Acta Neuropathologica · 20.05.2026 · 151 (1)

DOI: 10.1007/s00401-026-03022-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 20.05.2026. Verfasst von Marie Girodengo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Kinases and Brain Development Lab, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK. Hauptthemen laut MEDLINE: Tuberous Sclerosis, Brain, Astrocytoma, Brain Neoplasms. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NCI NIH HHS, Narodowym Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberous sclerosis complex (TSC) is a rare disease caused by mutations in TSC1 and TSC2, resulting in activation of mechanistic target of rapamycin complex 1 (mTORC1). Neurological manifestations in TSC patients include epilepsy, autism and intellectual disability. Two types of brain lesions, cortical tubers and subependymal giant cell astrocytomas (SEGAs), cause the majority of neurological manifestations in TSC. We have limited understanding of the molecular changes that occur in tubers and SEGAs and how these contribute to disease pathogenesis. To investigate this, we performed proteomic and phosphoproteomic analysis of TSC patient tuber and SEGA tissue. Tubers showed evidence of alterations in mitochondrial respiration, cytoskeleton organisation and neuronal function. However, we were unable to detect mTORC1 activation in tubers, likely due to the small number of cells with complete inactivation of TSC1 or TSC2 . By contrast, SEGAs showed evidence of strong mTORC1 activation and large-scale changes in the proteome and phosphoproteome. SEGAs exhibited increased expression of ribosomal proteins and activation of a neuroinflammatory response. Phosphoproteomics identified 6060 phosphosites within 2154 proteins increased in SEGAs. Phosphorylation of multiple proteins involved in RNA-metabolism, including mRNA splicing, was increased in SEGAs. Consistent with this, we found evidence of extensive alterations in mRNA transcript splicing in SEGA tissue that is shared with a wide range of cancers. These data greatly expand the repertoire of known mTORC1 target proteins in the human brain and reveal that large-scale mis-regulation of mRNA splicing may promote the formation of SEGAs in TSC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberous SclerosisBrainAstrocytomaBrain NeoplasmsHumansProteomicsTuberous Sclerosis Complex 2 ProteinFemaleMechanistic Target of Rapamycin Complex 1Tuberous Sclerosis Complex 1 ProteinPhosphorylationMaleChild

Stichwörter der Autor:innen

PhosphoproteomicsSEGASignallingTSCTubermTOR

Substanzen

Tuberous Sclerosis Complex 2 ProteinTSC2 protein, humanMechanistic Target of Rapamycin Complex 1Tuberous Sclerosis Complex 1 ProteinTSC1 protein, human

Autor:innen und Institutionen

  • Kinases and Brain Development Lab, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.
  • Department of Basic and Clinical Neuroscience, King's College London, 5 Cutcombe Road, London, SE5 9RX, UK.
  • Department of Cancer Genetics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
  • King's College Hospital, Denmark Hill, London, SE5 9RS, UK.
  • Proteomics Science Technology Platform, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.
  • Cancer Genetics Laboratory, Division of Pulmonary and Critical Care Medicine, Harvard Medical School Boston, Brigham and Women's Hospital, Boston, MA, USA.

Förderung

  • Medical Research Council
  • NCI NIH HHS
  • Narodowym Centrum Nauki
  • Wellcome Trust
  • Cancer Research UK
  • 2024 L’Oreal-UNESCO for Women in Science program in Poland
  • Engles Family Fund for Research in TSC and LAM
  • TSC Alliance Biosample Seed Grant

Zitieren

APA

Girodengo, M., Mihaylov, S. R., Klonowska, K., Mantoan Ritter, L., Flynn, H. R., Skehel, J. M., Bou Farhat, E., Aronica, E., White, M., Kwiatkowski, D. J., Ultanir, S. K., & Bateman, J. M. (2026). The phosphoproteomic landscape of the neurological manifestations in tuberous sclerosis complex. Acta Neuropathologica, 151(1). https://doi.org/10.1007/s00401-026-03022-5

Vancouver

Girodengo M, Mihaylov SR, Klonowska K, Mantoan Ritter L, Flynn HR, Skehel JM, et al. The phosphoproteomic landscape of the neurological manifestations in tuberous sclerosis complex. Acta Neuropathologica. 2026;151(1). doi:10.1007/s00401-026-03022-5

BibTeX
@article{Girodengo2026,
  author = {Girodengo, Marie and Mihaylov, Simeon R and Klonowska, Katarzyna and Mantoan Ritter, Laura and Flynn, Helen R and Skehel, J Mark and Bou Farhat, Elias and Aronica, Eleonora and White, Matthew and Kwiatkowski, David J and Ultanir, Sila K and Bateman, Joseph M},
  title = {The phosphoproteomic landscape of the neurological manifestations in tuberous sclerosis complex},
  journal = {Acta Neuropathologica},
  year = {2026},
  volume = {151},
  number = {1},
  doi = {10.1007/s00401-026-03022-5}
}
Kostenlos starten →